Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329027 · ClinicalTrials.gov registry record · NA
A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes
A NA study, sponsored by Vibrant.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT03329027: Completed NA study, sponsored by Vibrant.
NCT03329027 is a NA study that has completed, run by Vibrant. The registered enrollment target is 67 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03329027, a NA study, has completed, sponsored by Vibrant.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled pilot study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation in subjects with functional constipation. Three arms that assessed: * Vibrant Capsule with vibrating mode 1 administered 5 times per week * Vibrant Capsule with vibrating mode 2 administered 5 times per week * Sham Capsule administered 5 times per week
Primary Outcome
CSBM1 success rate, defined as an increase from the base line of at least one weekly Complete Spontaneous Bowel Movement (CSBM) during at least 6 of the 8 weeks of treatment
Interventions
- DEVICE Sham capsule
- DEVICE Vibrating Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2018-03-30 |
| Phase | NA |
What the finished NCT03329027 record still lists
NCT03329027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham capsule is the first listed.
NCT03329027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03329027 about?
NCT03329027 is a clinical study titled "A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes". The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled pilot study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation in subjects with functional constipation. Three arms that assessed: * Vibrant Capsule with vibrating mode 1...
What is the current status of trial NCT03329027?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2017-11-14. Estimated completion is 2018-03-30.
What interventions are being tested in trial NCT03329027?
The interventions under investigation include: Sham capsule (DEVICE), Vibrating Capsule (DEVICE).
Who is sponsoring clinical trial NCT03329027?
This trial is sponsored by Vibrant, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03329027's enrollment target sits among peer trials
67 1139th of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI